Atavistik Bio has dosed the first subject in its Phase I clinical trial of ATV-1601, designed to treat adults with solid tumours.

Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with Duchenne muscular dystrophy (DMD) with Sarepta and Roche’s Elevidys ...

Roche’s Genentech has reported new five-year data from the Phase III Portal trial of Susvimo for treating wet AMD.

Spine BioPharma's Phase III MODEL trial assessing SB-01 for people with CLBP associated with DDD failed to achieve its primary goal.

Eli Lilly's Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC trial of a disulfide small molecule, LP-300.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Recognify Life Sciences has reported that its Phase IIb trial of inidascamine to treat CIAS failed to achieve its primary goal.

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Shares in Celcuity climbed by 233.76% at market open on 28 July after it reported the Phase III breast cancer data.